Ask about this productRelated genes to: Vgll2 Blocking Peptide
- Gene:
- VGLL2 NIH gene
- Name:
- vestigial like family member 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-30
- Date modifiied:
- 2016-10-05
Related products to: Vgll2 Blocking Peptide
Related articles to: Vgll2 Blocking Peptide
- Rhabdomyosarcoma (RMS) contributes to 3% of all childhood cancers with roughly 400-500 cases diagnosed each year in the United States. The World Health Organization classifies rhabdomyosarcoma into four histological subtypes which include alveolar, embryonal, spindle-cell and pleomorphic. The primary genetic drivers in a subset of alveolar and spindle-cell histological subtypes are gene fusions. This review explores the fusion oncogenes identified in RMS such as and based fusions, along with discussing studies defining fusion oncogene biology and tumorigenic mechanisms. Focus areas include data around transformation events and progression along with dysregulated biological processes. Furthermore, we summarize model systems, ranging from cell to animal models, that have been implemented to study fusion oncogenes identified in RMS. With the constant identification of novel fusion oncogenes, this review also emphasizes the need for genetically characterizing RMS tumors and rapidly developing new model systems. These models are critical to study fusion oncogene activity and to delineate key regulatory players and potential therapeutic targets that suppress tumorigenesis. The identification of RMS fusion oncogenes and integration with animal and cell culture models will help identify conserved molecular targets, optimize therapeutic approaches, and ultimately improve clinical outcomes for children with RMS. - Source: PubMed
Publication date: 2025/06/17
Sankhe Chinmay SHall LisaKendall Genevieve C - This study aimed to leverage bioinformatics approaches to identify novel biomarkers and characterize the molecular mechanisms underlying hypertrophic cardiomyopathy (HCM). - Source: PubMed
Publication date: 2025/06/17
Zhang FengLi ChunruiZhang Lulu - Studies on Hippo pathway regulation of tumorigenesis largely center on YAP and TAZ, the transcriptional co-regulators of TEADs. Here, we present an oncogenic mechanism involving VGLL and TEAD fusions that is Hippo pathway-related but YAP/TAZ-independent. We characterize two recurrent fusions, and , recently identified in human spindle cell rhabdomyosarcoma. We demonstrate that in contrast to VGLL2 and TEAD1 the fusion proteins are potent activators of TEAD-dependent transcription, and the function of these fusion proteins does not require YAP/TAZ. Furthermore, we identify that VGLL2 and TEAD1 fusions engage specific epigenetic regulation by recruiting histone acetyltransferase EP300 to control TEAD-mediated transcriptional and epigenetic landscapes. We show that small-molecule EP300 inhibition can suppress fusion protein-induced oncogenic transformation both in vitro and in vivo in mouse models. Overall, our study reveals a molecular basis for VGLL involvement in cancer and provides a framework for targeting tumors carrying , , or translocations. - Source: PubMed
Publication date: 2025/05/08
Guo SusuHu XiaodiCotton Jennifer LMa LifangLi QiCui JiangtaoWang YongjieThakare Ritesh PTao ZhipengIp Y TonyWu XuWang JiayiMao Junhao - Vestigial-like family member 1 (VGLL1), a product of an X-linked gene (VGLL1), belongs to a family of transcriptional co-activators including VGLL2, VGLL3 and VGLL4. These proteins are called vestigial-like because of the structural and functional similarities with the Drosophila ortholog vestigial (vg). VGLL1 is usually expressed in human placenta, and has also been detected in many aggressive cancers. For this reason, it is called an onco-placental protein. It can bind and activate the TEA-domain containing transcription factors TEAD1-4, and the interaction is mediated through a conserved 'valine-x-x-histidine-phenylalanine' domain (VxxHF, x denotes any amino acid) present in VGLL1 protein. Prior studies indicate a pro-tumorigenic role for this protein in several cancers including carcinoma of the breast. This review aims at summarizing our present knowledge about the functions of VGLL1, and the mechanisms that regulate its expression in cancer. - Source: PubMed
Publication date: 2025/04/24
Parimita ShubhashreeDas AmitavaSamanta Sanjoy - An efficient promoter with specific transcriptional activity plays significant roles in the regulation of expression of exogenous genes. The efficient promoter specific to skeletal muscles can achieve high expression of exogenous genes in skeletal muscles. This is of great significance for the targeted improvement of livestock meat quality by combining gene editing and traditional breeding techniques. To identify efficient promoters specific to the skeletal muscles of buffalo, in the present study, a total of 14 genes, , , , , , , , , , , , , , and , were firstly screened as skeletal-muscle-specific expressed genes based on high-throughput sequencing data. Among them, only two genes - namely, and - were identified to be specifically and efficiently expressed in the skeletal muscles of buffalo by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Then, the transcriptional activity of different truncated fragments of the upstream putative promoter region of and were evaluated by the dual luciferase reporter gene detection system in mouse C2C12 cells and buffalo skeletal muscle cells. As a result, both core promoters of and were identified to have specifically and efficiently transcriptional activity in skeletal muscle tissue while the transcriptional activity of the core promoters of was more efficient. These results provide significant information for the targeted improvement of meat quality in buffaloes and other livestock animals. - Source: PubMed
Publication date: 2025/01/31
Huang JiepingGuo DuoZhu RuiruiWang HaopengYang ChunyanShi DeshunShang Jianghua